Skip to main content
. 2022 Dec 20;1(1):e000277. doi: 10.1136/bmjmed-2022-000277

Figure 4.

Figure 4

Associations of genetically proxied lipid lowering and antihypertensive therapies with hepatic fat. The associations for genetically proxied lipid lowering target was scaled to a decrease of 10 mg/dL low density lipoprotein cholesterol concentrations. The associations for genetically proxied antihypertensive target was scaled to a decrease of 10 mm Hg systolic blood pressure. The x axis unit is standard deviation (SD) change in liver fat percentage. One SD increase is approximately a 4.25 unit increase of absolute liver fat percentage points. CI=confidence interval; HMGCR=3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; LDLR=low density lipoprotein receptor; NPC1L1=Niemann-Pick C1-like 1; PCSK9=proprotein convertase subtilisin/kexin type 9